Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12531397 | 0.89 | L3MBTL1 (0.67) | GRM5ALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4702193 | 0.83 | GRM5 (0.64) | GRM5ALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL13316190 | 0.83 | GRM5 (0.64) | GRM5ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL4702196 | 0.83 | GRM5 (0.64) | GRM5ALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL12531379 | 0.82 | L3MBTL1 (0.62) | GRM5ALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL13315137 | 0.81 | GRM5 (0.73) | GRM5ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL188053 | 0.81 | SMN1; SMN2 (0.79) | ALDH1A1SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13503934 | 0.80 | GRM5 (0.60) | GRM5ALDH1A1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4830376 | 0.80 | GRM5 (0.71) | GRM5ALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL5724695 | 0.80 | GRM5 (0.59) | GRM5ALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | GRM5 254/4885ALDH1A1 2886/4885L3MBTL1 1414/4885 |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | GRM5 254/4885ALDH1A1 2886/4885L3MBTL1 1414/4885 |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | GRM5 254/4885ALDH1A1 2886/4885L3MBTL1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.